Analogix Introduces SlimPort Mobile Device to Display Accessories
Semiconductor Company Enters Accessory Market, Launches SlimPortConnect.com
Analogix Semiconductor , the market leader in enabling DisplayPort™ products, announced it has entered the accessory market. The new line of SlimPort® accessories feature a microUSB adapter that connects SlimPort or MyDP (Mobility DisplayPort) enabled mobile phones and tablets to any HD projector, TV, computer or monitor for multi-display productivity and big screen entertainment.
“Using next generation smartphones and tablets with integrated SlimPort products combined with SP accessories will make it easy to own most any screen wherever you go,” said Andre Bouwer, vice president of marketing for Analogix. “Multi-screen multi-tasking will become a reality, while sharing content with friends, family and colleagues will be simpler than ever.”
Coming to market in the next couple of months, tablets and smartphones featuring SlimPort capabilities will be equipped to display true full HD (1080p at 60Hz) media on any screen, even in 3D, all while preserving battery life. Analogix is releasing a total of four supporting microUSB cables and adapters with connectivity through most popular display standards - HDMI, VGA, DVI and DisplayPort.
“The VESA MyDP specification, based on globally adopted DisplayPort technology, was designed specifically to make media sharing high quality and intuitive to connect,” said Mike Engbretson, chief technology engineer of Granite River Labs . “We are very pleased to have certified the source silicon for the industry’s first MyDP product, and look forward to working with Analogix and their customers to certify SlimPort active adapters and mobile devices. MyDP certification is critical to the successful launch of SlimPort and assures customers that the products meet expected compliance and interoperability requirements.”
The first in the series, model SP1002, is immediately available in both the US and Europe on Amazon for $29.99 (USD). At the same time, Analogix has launched, SlimPortConnect.com where consumers can find information about SlimPort devices and accessories, the benefits of such solutions, where to buy and more.
About Granite River Labs
With lab locations in Santa Clara, Calif., and Taipei and Hsinchu in Taiwan, Granite River Labs provides a range of engineering services to help customers adopt multi-gigabit connectivity technologies from the IC to system level, including compliance testing, debugging, device characterization, signal/power integrity modeling and simulation, stress testing, benchmarking, and interoperability. Information about GRL is available www.graniteriverlabs.com .
About Analogix Semiconductor
Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smart phones to high-end graphics cards and large, high-definition displays. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort, including the SlimPort family of products. For more information visit www.analogix.com or follow us on Twitter @Analogix.
Analogix and SlimPort are trademarks or registered trademarks of Analogix Semiconductor, Inc. All other trademarks and trade names are the property of their respective owners.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50456070&lang=en
Contact:
Stowe Consulting for Analogix
Kim Stowe, 408-839-8750 (Media)
kim@stoweconsulting.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom